New study tracks bladder control after prostate surgery
NCT ID NCT06351579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 30 men aged 45-70 who had their prostate removed due to cancer. Researchers measured urine leakage by weighing pads over 24 hours and during a 1-hour activity test. The goal was to better understand how long and how severe incontinence lasts after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will enroll male subjects diagnosed with prostate cancer who are scheduled for radical prostatectomy. Subjects must meet all the inclusion criteria and none of the exclusion criteria to participate in the study.
- Ages
-
45 to 70 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male 45-70 years of age 2. Diagnosed with prostate cancer and scheduled for radical prostatectomy 3. Gleason Grade Group 3 or lower 4. Prostate size less than 80 grams 5. Able and willing to provide written consent to participate in the study 6. Able and willing to comply with study follow-up visits and procedures Exclusion Criteria: 1. Malignant tumors outside of the prostate capsule confirmed via baseline assessments (e.g., mpMRI, bone scan) 2. History of urinary incontinence, including stress or urge urinary incontinence 3. On medications to treat overactive bladder (OAB) 4. Presence of urethral stricture or bladder neck contracture 5. Current or chronic urinary tract infection 6. Prior urologic outlet surgical or minimally invasive procedure (e.g., TURP, HoLEP, Rezum, etc.). 7. Prior pelvic radiation or anticipated need for radiation after radical prostatectomy 8. Presence of stones in the bladder 9. History of neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function 10. Body mass index \>35 11. History of cancer (excluding prostate cancer meeting the inclusion criteria) which is not considered in complete remission - a potential participant is considered cured if there has been no evidence of cancer within five years of enrollment 12. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function, sphincter function or poor detrusor muscle function 13. History of clinically significant congestive heart failure (i.e., New York Heart Association (NYHA) Class III and IV) 14. Insulin-dependent diabetes mellitus 15. Current uncontrolled diabetes (i.e., hemoglobin A1c ≥7.5%) 16. Intravesical prostatic protrusion (IPP) \>5mm 17. History of immunosuppressive conditions (e.g., AIDS, post-transplant) 18. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study per investigator discretion 19. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affect the ability to complete the study quality of life questionnaires 20. Subject currently participating in other investigational studies unless approved by the Sponsor in writing
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BPH are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LeeveMedical, Inc
Durham, North Carolina, 27703, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?